2001
DOI: 10.1128/jvi.75.10.4941-4946.2001
|View full text |Cite
|
Sign up to set email alerts
|

Patient-Specific Cytotoxic T-Lymphocyte Cross-Recognition of Naturally Occurring Variants of a Human Immunodeficiency Virus Type 1 (HIV-1) p24gagEpitope by HIV-1-Infected Children

Abstract: We tested seven human immunodeficiency virus-infected children for their cytotoxic T-lymphocyte (CTL) activities towards the p24 gag QASQEVKNW epitope and its nine variant sequences. Our data confirm that most, but not all, CTL responses are broadly cross-specific. For the first time, we show the high interpatient variability in cross-recognition of mutant CTL epitopes. These interindividual variations in the CTL response to the same epitope should be taken into account in the design and the evaluation of vacc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
9
0

Year Published

2001
2001
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(13 citation statements)
references
References 25 publications
4
9
0
Order By: Relevance
“…The efficient cross-reactivity of T cells specific for the B58-restricted gag 241-50 epitope in HIV-2 extends the data from a previous study in HIV-2-infected patients, the majority of whom had gagspecific CTL lines capable of cross-recognizing HIV-1 gag, with some having lytic responses to the gag 240 -252 region on peptide mapping (38). We observed some variability between individuals in the amount of cross-recognition as suggested from previous studies (38,39). Although the differences we identified may have a degree of epitope selectivity (40,41), the global molecular analysis points to an overall reduction in large oligoclonal expansions in the total virus-specific response to HIV-2 compared with HIV-1 infection.…”
Section: Discussionsupporting
confidence: 79%
“…The efficient cross-reactivity of T cells specific for the B58-restricted gag 241-50 epitope in HIV-2 extends the data from a previous study in HIV-2-infected patients, the majority of whom had gagspecific CTL lines capable of cross-recognizing HIV-1 gag, with some having lytic responses to the gag 240 -252 region on peptide mapping (38). We observed some variability between individuals in the amount of cross-recognition as suggested from previous studies (38,39). Although the differences we identified may have a degree of epitope selectivity (40,41), the global molecular analysis points to an overall reduction in large oligoclonal expansions in the total virus-specific response to HIV-2 compared with HIV-1 infection.…”
Section: Discussionsupporting
confidence: 79%
“…Thus, also stimulation with A/Victoria/3/75 (H3N2) led to the expansion of NP DSI -specific cells cross-reactive with NP DTI . This finding resembles the cross-reactivity observed with CTL specific for epitopes in HIV-1, dengue virus, and SIV (33)(34)(35). HIV-1-specific CTL could recognize variants of epitopes present in different clades of this virus.…”
Section: Discussionsupporting
confidence: 52%
“…There is increasing evidence that both CD4 ϩ and CD8 ϩ subsets are probably required for strong CTL memory and protection against HIV-1 (51, 55, 58). HIV-1 Gag is one of the most conserved viral proteins, and broad, cross-clade CTL responses recognizing conserved epitopes in HIV-1 Gag have been detected in HIV-1-infected individuals (5,8,23). Therefore, the induction of CTL and T-helper responses against conserved Gag epitopes via fusogenic HIV-1 or heterologous envelope-mediated targeting of Gag particles to APC in vivo could be significant for the development of a safe and effective HIV-1 DNA vaccine.…”
Section: Fig 5 Cd4mentioning
confidence: 99%
“…It was constructed by inverting a BamHI-BamHI fragment encompassing the VSV-G gene in pCMV-VSV. Plasmid pCMV-VSV mut encodes a fusion-defective VSV-G protein (mutant Q117N) (8,70).…”
Section: Hiv-1 Gag and Vsv-g Expression Vectorsmentioning
confidence: 99%